CC
CCCC.US C4 Therapeutics Inc
- Market cap
- USD 364M
- P/E
- -
- P/B
- 1.60x
- ROE
- -41.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CCCC.US undervalued?
Graham numberThe Graham number of C4 Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
C4 Therapeutics Inc fundamental analysis
No fundamental analysis for C4 Therapeutics Inc yet.
C4 Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective …
Full company profileC4 Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
C4 Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 19.4M | 21.4M | 33.2M | 45.8M | 31.1M | 20.8M | 35.6M | 35.9M | 28.3M |
| Gross Profit | -9.23M | 21.4M | -45.2M | 45.8M | 31.1M | 13.0M | 35.6M | 28.0M | 25.9M |
| Operating Income | -16.4M | -35.5M | -60.4M | -82.1M | -130M | -139M | -120M | -104M | -105M |
| EBITDA | -15.1M | -31.7M | -58.8M | -80.3M | -124M | -128M | -103M | -103M | -96.5M |
| Net Income | -15.7M | -34.1M | -66.3M | -83.9M | -128M | -132M | -105M | -105M | -94.1M |
| EPS | -0.37 | -0.79 | -1.54 | -1.82 | -2.62 | -2.67 | -1.52 | -1.27 | -0.69 |
| Balance Sheet | |||||||||
| Total Assets | 146M | 118M | 400M | 507M | 431M | 376M | 350M | 359M | 332M |
| Total Liabilities | 226M | 230M | 119M | 117M | 142M | 130M | 134M | 102M | 104M |
| Shareholders' Equity | -79.8M | -112M | 281M | 390M | 289M | 246M | 216M | 257M | 228M |
| Cash & Short-term Investments | 36.3M | 90.5M | 372M | 309M | 276M | 254M | 245M | 249M | 205M |
| Total Debt | 14.5M | 13.7M | 22.9M | 42.9M | 87.2M | 71.0M | 65.8M | 60.0M | 55.2M |
| Cash Flow | |||||||||
| Operating Cash Flow | -17.0M | 55.6M | -67.2M | -87.0M | -106M | -107M | -65.2M | -98.7M | -76.6M |
| Capital Expenditure | 2.69M | 1.35M | 650K | 1.28M | 5.50M | 1.71M | 180K | 607K | 135K |
| Free Cash Flow | -19.7M | 54.3M | -67.9M | -88.2M | -111M | -109M | -65.3M | -99.3M | -76.8M |
| Ratios | |||||||||
| ROE | - | - | -23.6% | -21.5% | -44.3% | -53.8% | -48.8% | -40.9% | -41.3% |
| ROA | -10.7% | -28.8% | -16.6% | -16.6% | -29.8% | -35.2% | -30.1% | -29.2% | -28.4% |
| Net Profit Margin | -81.1% | -159.5% | -199.8% | -183.2% | -412.2% | -638.3% | -296.0% | -292.1% | -332.1% |
| Debt to Equity | - | - | 0.08x | 0.11x | 0.30x | 0.29x | 0.30x | 0.23x | 0.24x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
C4 Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 12.0M | 0.28 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns C4 Therapeutics Inc
- Insiders 0.79%
- Institutions 98.87%
- Public & others 0.34%
- Shares outstanding 131M
- Free float 103M
Top funds holding CCCC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.26M | 2.49% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 2.60M | 1.98% | 0.00% | Oct 2026 |
| Wasatch Ultra Growth | 1.54M | 1.17% | -38.67% | Sep 2026 |
| Fidelity Small Cap Index | 1.11M | 0.85% | +0.34% | Aug 2026 |
| Fidelity Enhanced Small Cap Core ETF | 1.09M | 0.83% | +0.27% | Oct 2026 |
| iShares Russell 2000 Value ETF | 931K | 0.71% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 875K | 0.67% | -0.19% | Oct 2026 |
| Wasatch Micro Cap | 762K | 0.58% | 0.00% | Sep 2026 |
| JNL Multi-Manager Small Cap Value I | 634K | 0.48% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 590K | 0.45% | +1.01% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 553K | 0.42% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 501K | 0.38% | +8.89% | Sep 2026 |
| Vanguard US Momentum Factor ETF | 403K | 0.31% | 0.00% | Sep 2026 |
| CREF Total Global Stock Account R3 | 354K | 0.27% | +54.67% | Aug 2026 |
| iShares Micro-Cap ETF | 308K | 0.23% | 0.00% | Oct 2026 |
| Northern Small Cap Value | 307K | 0.23% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 271K | 0.21% | 0.00% | Oct 2026 |
| Schwab Small-Cap Equity | 262K | 0.20% | 0.00% | Sep 2026 |
| Schwab Small Cap Index | 246K | 0.19% | 0.00% | Sep 2026 |
| GuideStone Funds Small Cap Equity Instl | 235K | 0.18% | 0.00% | Oct 2026 |
Top institutions holding CCCC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Morgan Stanley - Brokerage Accounts | 8.87M | 6.75% | -2.26% | Jun 2026 |
| RA Capital Management, LLC | 8.00M | 6.09% | 0.00% | Jun 2026 |
| BlackRock Inc | 7.90M | 6.01% | +285.48% | Jun 2026 |
| Lynx1 Capital Management, LP | 7.33M | 5.58% | +4.68% | Jun 2026 |
| Squadron Capital Management LLC | 7.20M | 5.48% | +220.00% | Jun 2026 |
| Bain Capital Life Sciences Investors, LLC | 7.17M | 5.46% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 4.75M | 3.62% | +47.30% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.42M | 3.36% | +14.39% | Jun 2026 |
| Citadel Advisors Llc | 4.19M | 3.19% | +66.77% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.53M | 2.69% | +47.90% | Jun 2026 |
| Wasatch Advisors LP | 3.52M | 2.68% | +18.94% | Jun 2026 |
| Two Sigma Investments LLC | 3.47M | 2.64% | +14.30% | Jun 2026 |
| Soleus Capital Management, L.P. | 3.38M | 2.57% | -11.20% | Jun 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 3.03M | 2.31% | +58.60% | Jun 2026 |
| Bank of America Corp | 2.66M | 2.02% | +12.59% | Jun 2026 |
| Geode Capital Management, LLC | 2.52M | 1.92% | +165.20% | Jun 2026 |
| Ikarian Capital, LLC | 2.43M | 1.85% | 0.00% | Jun 2026 |
| State Street Corp | 2.12M | 1.61% | +452.42% | Jun 2026 |
| Acadian Asset Management LLC | 1.81M | 1.38% | -4.48% | Jun 2026 |
| Candriam Luxembourg S.C.A. | 1.80M | 1.37% | 0.00% | Jun 2026 |
C4 Therapeutics Inc company profile
- Company name
- C4 Therapeutics Inc
- Ticker
- CCCC.US
- Exchange
- USA Stocks
- Listed since
- Oct 2, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 104
- Fiscal year end
- December
- Address
- 490 Arsenal Way, Watertown, MA, United States, 02472
- Phone
- 617 231 0700
- Website
- c4therapeutics.com
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
C4 Therapeutics Inc management
10- Mr. Andrew J. Hirsch M.B.A.CEO, President & Director · born 1971
- Dr. Kenneth C. Anderson M.D., Ph.D.Co-Founder, Independent Director & Member of Scientific Advisory Board · born 1951
- Ms. Kendra R. AdamsPrincipal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer · born 1977
- Dr. Leonard M. J. Reyno M.D.Chief Medical Officer · born 1962
- Dr. Nathanael S. Gray Ph.D.Co-Founder & Member of Scientific Advisory Board
- Ms. Courtney SolbergSenior Manager of Investor Relations
- Ms. Kelly A. SchickChief People Officer · born 1980
- Dr. Isabel Chiu Ph.D.Senior Vice President of Strategic Alliances & Business Development
- Dr. Christopher NasveschukSenior Vice President of Chemistry
- Mr. Roy Pollock Ph.D.Senior Vice President of Biological Sciences